Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

These miniature immune system models — known as human immune organoids — mimic the real-life environment where immune cells ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

German life sciences company Merck KGaA (MRK: DE) today announced that the Phase III MANEUVER trial of pimicotinib met its ...

Watertown, Mass., added millions of square feet of lab space in just a few years. Here's how it happened, and why the pace ...

Cepheid congratulates Executive Vice President, Chief Medical and Scientific Officer, David H. Persing, MD, Ph.D., for receiving the 2024 California Life Sciences (CLS) Pantheon Leadership award. The ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...